Cowen & Co. Maintains a Buy Rating on Epizyme (EPZM)

By Ryan Adsit

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Epizyme (EPZMResearch Report), with a price target of $18. The company’s shares closed yesterday at $11.46.

According to, Werber is a 5-star analyst with an average return of 12.9% and a 61.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $20.60 average price target, implying a 79.8% upside from current levels. In a report issued on May 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $25 price target.

See today’s analyst top recommended stocks >>

Based on Epizyme’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $29.34 million. In comparison, last year the company had a GAAP net loss of $34.07 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.